Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Zacks Investment Research8/11/2026Positive
INGN
Inogen IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$151.53M
P/E Ratio
—
EPS
$-0.90
Beta
1.60
52W High
$9.13
52W Low
$5.34
50-Day MA
$6.43
200-Day MA
$6.55
Dividend Yield
—
Profit Margin
-6.94%
Forward P/E
—
PEG Ratio
3.48
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Fundamentals
| Revenue (TTM) | $354.30M |
| Gross Profit (TTM) | $157.69M |
| EBITDA | $-8.09M |
| Operating Margin | -5.13% |
| Return on Equity | -13.10% |
| Return on Assets | -5.84% |
| Revenue/Share (TTM) | $13.05 |
| Book Value | $6.68 |
| Price-to-Book | 0.88 |
| Price-to-Sales (TTM) | 0.43 |
| EV/Revenue | 0.179 |
| EV/EBITDA | -17.60 |
| Quarterly Earnings Growth (YoY) | 87.30% |
| Quarterly Revenue Growth (YoY) | 3.00% |
| Shares Outstanding | $26.54M |
| Float | $23.14M |
| % Insiders | 12.89% |
| % Institutions | 80.47% |
Historical Volatility
HV 10-Day
44.48%
HV 20-Day
42.10%
HV 30-Day
38.72%
HV 60-Day
43.25%
HV Rank
20.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($12.67 target)
1
Strong Buy2
BuyLatest News
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Zacks Investment Research8/11/2026Negative
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.
Zacks Investment Research8/10/2026Neutral
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Seeking Alpha8/7/2026Neutral
Inogen Q2 Earnings Call Highlights
Inogen NASDAQ: INGN reported second-quarter 2026 revenue of $95.1 million, up 3% from a year earlier, as international growth, portable oxygen concentrator demand and contributions from newer products offset continued pressure in its U.S. direct-to-consumer business.
MarketBeat8/7/2026Negative
Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026.
Business Wire7/16/2026Neutral
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces the Appointment of Andy Reding as Chief Operating Officer.
Business Wire7/1/2026Neutral
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC strength, expanding respiratory portfolio and international momentum support growth, though U.S. revenue pressure remains a key risk.
Zacks Investment Research6/25/2026Positive
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.
Zacks Investment Research5/22/2026Neutral
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INGN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026